Resource Summary Report

Generated by <u>NIF</u> on May 15, 2025

Fred Hutchinson Cancer Center Experimental Histopathology Core Facility

RRID:SCR_022612 Type: Tool

Proper Citation

Fred Hutchinson Cancer Center Experimental Histopathology Core Facility (RRID:SCR_022612)

Resource Information

URL: <u>https://www.fredhutch.org/en/research/shared-resources/core-facilities/experimental-histopathology.html</u>

Proper Citation: Fred Hutchinson Cancer Center Experimental Histopathology Core Facility (RRID:SCR_022612)

Description: Provides expertise in anatomic pathology technologies. Offers routine and special staining,? immunohistochemistry, in situ hybridization and digital pathology in support of internal and external investigators who rely on histological analysis.

Synonyms: Fred Hutchinson Cancer Center Experimental Histopathology Shared Resource

Resource Type: service resource, core facility, access service resource

Keywords: anatomic pathology technologies, staining, ? immunohistochemistry, in situ hybridization, digital pathology, ABRF, USEDit

Funding:

Availability: Open

Resource Name: Fred Hutchinson Cancer Center Experimental Histopathology Core Facility

Resource ID: SCR_022612

Record Creation Time: 20220802T050144+0000

Ratings and Alerts

No rating or validation information has been found for Fred Hutchinson Cancer Center Experimental Histopathology Core Facility.

No alerts have been found for Fred Hutchinson Cancer Center Experimental Histopathology Core Facility.

Data and Source Information

Source: <u>SciCrunch Registry</u>

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at <u>NIF</u>.

Graham JB, et al. (2024) Regulatory T cells restrict immunity and pathology in distal tissue sites following a localized infection. Mucosal immunology, 17(5), 923.

Rominger MC, et al. (2024) Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state. bioRxiv : the preprint server for biology.

Garcia NMG, et al. (2023) APOBEC3 activity promotes the survival and evolution of drugtolerant persister cells during acquired resistance to EGFR inhibitors in lung cancer. bioRxiv : the preprint server for biology.